Company news

Akebia Therapeutics, Inc. news in 2025

Akebia Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Akebia Announces Establishment of Rare Kidney Disease Pipeline

November 30, 2025

Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

November 23, 2025

Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 9, 2025

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

November 5, 2025

Akebia Therapeutics to Present at Upcoming Investor Conferences

November 3, 2025

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights

October 29, 2025

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

October 27, 2025

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025

October 19, 2025

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

August 20, 2025

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 6, 2025

Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference

August 6, 2025

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

August 3, 2025

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

July 30, 2025

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

July 7, 2025

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

June 3, 2025

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

May 27, 2025

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

May 26, 2025

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 12, 2025

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

April 30, 2025

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

April 2, 2025

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

March 24, 2025

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

March 18, 2025

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

March 18, 2025

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

March 12, 2025

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

March 5, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 3, 2025

Akebia Therapeutics Announces Multiple Positive Business Updates

January 12, 2025

Calls in 2025

Decks in 2025